胰高血糖素样肽-1受体激动剂在糖尿病肾病中的研究进展  

Research progress of glucagon-like peptide-1 receptor agonists in diabetic nephropathy

作　　者：王葳 范瑛 汪年松[1] WANG Wei;FAN Ying;WANG Niansong(Department of Nephrology,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China)

机构地区：[1]上海交通大学医学院附属第六人民医院肾脏内科,上海200233

出　　处：《世界临床药物》2025年第1期8-13,共6页World Clinical Drug

基　　金：国家自然基金面上项目(82270761);国家重点研发计划(2023YFC2411803);上海市重中之重研究中心建设项目[2022ZZ01002(3)];上海市进一步加快中医药传承创新发展三年行动计划[ZY(2021-2023)-0205-04]。

摘　　要：胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)目前已被广泛用于2型糖尿病(type 2 diabetes mellitus)患者的治疗。GLP-1RA亦有助于改善糖尿病肾病(diabetic nephropathy,DN)患者的肾脏结局。GLP-1RA通过抑制炎症反应、降低氧化应激、减轻晚期糖基化终末产物诱导的损伤和改善代谢异常等途径发挥肾脏保护作用,在预防和减缓DN发生发展方面潜力巨大。现就GLP-1RA应用于DN的临床证据和作用机制进行综述,为临床提供参考。Glucagon-like peptide-1 receptor agonist(GLP-1RA)has been widely used in the treatment of patients with type 2 diabetes mellitus.GLP-1RA can also help improve renal outcomes in patients with diabetic nephropathy(DN).GLP-1RA plays a renal protective role by inhibiting inflammatory response,reducing oxidative stress,alleviating damage induced by advanced glycosylation end products and improving metabolic abnormalities,and has great potential in preventing and slowing down the occurrence and development of DN.This article reviewed the clinical evidence and mechanism of GLP-1RA in DN,so as to provide reference for clinical use.

关 键 词：胰高血糖素样肽-1受体激动剂 糖尿病肾病 肾脏保护 

分 类 号：R692.5[医药卫生—泌尿科学] R692[医药卫生—外科学]